Email: cspc@cspc.cn
News
News Center
Nov. 24
2025
VOLUNTARY ANNOUNCEMENT - A DOUBLE-STRANDED SMALL INTERFERING RNA DRUG (SYH2061 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Nov. 21
VOLUNTARY ANNOUNCEMENT - A SELECTIVE 5-HT2A RECEPTOR AGONIST (SYH2056 TABLETS) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Nov. 12
VOLUNTARY ANNOUNCEMENT - MARKETING AUTHORISATION APPLICATION FOR PERTUZUMAB INJECTION ACCEPTED BY THE NMPA
Oct. 24
VOLUNTARY ANNOUNCEMENT - SYH2061 INJECTION (A DOUBLE-STRANDED SMALL INTERFERING RNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Oct. 20
VOLUNTARY ANNOUNCEMENT - JSKN003 GRANTED ANOTHER BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR THE TREATMENT OF PATIENTS WITH HER2-POSITIVE ADVANCED COLORECTAL
Oct. 13
VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION FOR EFMEDAGLUTIDE ALFA INJECTION ACCEPTED BY THE NMPA
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
